We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

94 hedge funds and large institutions have $639M invested in Epizyme, Inc in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,498% more call options, than puts

Call options by funds: $783K | Put options by funds: $49K

110% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 10

13% more funds holding

Funds holding: 8394 (+11)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 29

9% less capital invested

Capital invested by funds: $699M → $639M (-$60.1M)

Holders
94
Holders Change
+11
Holders Change %
+13.25%
% of All Funds
2.73%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
21
Increased
29
Reduced
29
Closed
10
Calls
$783K
Puts
$49K
Net Calls
+$734K
Net Calls Change
+$311K
Name Holding Trade Value Shares
Change
Change in
Stake
NMC
1
NEA Management Company
Maryland
$140M -$40.3M -1,296,349 -20%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$118M +$14.3M +459,800 +12%
MAM
3
MPM Asset Management
Massachusetts
$65.4M
Primecap Management
4
Primecap Management
California
$38.5M +$7.33M +236,000 +20%
Vanguard Group
5
Vanguard Group
Pennsylvania
$27.6M +$9.56M +307,504 +43%
QF
6
QVT Financial
New York
$27.4M
Lord, Abbett & Co
7
Lord, Abbett & Co
New Jersey
$20.8M +$12.4M +400,214 +109%
State Street
8
State Street
Massachusetts
$18.8M +$16.8M +541,371 +352%
BFA
9
BlackRock Fund Advisors
California
$18.7M +$431K +13,878 +2%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$15.9M +$1.9M +61,240 +12%
GGHC
11
Gilder Gagnon Howe & Co
New York
$15.5M -$171K -5,498 -1%
JP Morgan Chase
12
JP Morgan Chase
New York
$13.6M +$15.5K +500 +0.1%
Capital World Investors
13
Capital World Investors
California
$10.4M
PA
14
Perceptive Advisors
New York
$7.7M +$7.5M +241,288 +566%
EA
15
Emerald Advisers
Pennsylvania
$7.32M -$320K -10,300 -4%
EMFAT
16
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.8M -$33.3K -1,070 -0.4%
Citadel Advisors
17
Citadel Advisors
Florida
$6.17M +$6.59M +211,993 +1,360%
Wellington Management Group
18
Wellington Management Group
Massachusetts
$5.9M -$234K -7,540 -3%
BBA
19
Baker Bros. Advisors
New York
$5.8M
DCM
20
Driehaus Capital Management
Illinois
$4.86M -$2.58M -82,952 -32%
UBS AM
21
UBS AM
Illinois
$4.71M -$1.84M -59,168 -25%
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$4.19M +$4.81M +154,721 New
NI
23
Numeric Investors
Massachusetts
$3.95M +$4.53M +145,800 New
Northern Trust
24
Northern Trust
Illinois
$3.89M +$1.7M +54,751 +62%
TCM
25
Tekla Capital Management
Massachusetts
$3.83M +$2.21M +71,100 +101%

EPZM Hedge Fund Activity: Q3 2014 in Review

94 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2014, worth a combined $639M — down 8.6% from $699M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new EPZM positions and 10 closed out — a net gain of 11 holders — while 29 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $16.8M. The largest seller was NEA Management Company, cutting an estimated $40.3M.

  • 94 institutional investors held Epizyme, Inc (EPZM) as of Q3 2014, up from 83 in Q2 2014.
  • Funds reported $639M of Epizyme, Inc stock for Q3 2014, down 8.6% quarter-over-quarter.
  • 21 funds opened new Epizyme, Inc positions in Q3 2014 and 10 closed out, a net change of +11 holders.
  • The largest Epizyme, Inc buyer in Q3 2014 was State Street, an estimated $16.8M added.
  • The largest Epizyme, Inc seller in Q3 2014 was NEA Management Company, an estimated $40.3M sold.

Based on aggregated 13F filings for Q3 2014.